Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes

Soro-Paavonen, Aino, Watson, Anna M. D., Li, Jiaze, Paavonen, Karri, Koitka, Audrey, Calkin, Anna C., Barit, David, Coughlan, Melinda T., Drew, Brian G., Lancaster, Graeme I., Thomas, Merlin, Forbes, Josephine M., Nawroth, Peter P., Bierhaus, Angelika, Cooper, Mark E. and Jandeleit-Dahm, Karin A. (2008) Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes, 57 9: 2461-2469. doi:10.2337/db07-1808

Author Soro-Paavonen, Aino
Watson, Anna M. D.
Li, Jiaze
Paavonen, Karri
Koitka, Audrey
Calkin, Anna C.
Barit, David
Coughlan, Melinda T.
Drew, Brian G.
Lancaster, Graeme I.
Thomas, Merlin
Forbes, Josephine M.
Nawroth, Peter P.
Bierhaus, Angelika
Cooper, Mark E.
Jandeleit-Dahm, Karin A.
Title Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes
Journal name Diabetes   Check publisher's open access policy
ISSN 0012-1797
Publication date 2008-09
Sub-type Article (original research)
DOI 10.2337/db07-1808
Open Access Status Not yet assessed
Volume 57
Issue 9
Start page 2461
End page 2469
Total pages 9
Place of publication Alexandria, VA, United States
Publisher American Diabetes Association
Language eng
Formatted abstract
Objective: Activation of the receptor for advanced glycation end products (RAGE) in diabetic vasculature is considered to be a key mediator of atherogenesis. This study examines the effects of deletion of RAGE on the development of atherosclerosis in the diabetic apoE-/- model of accelerated atherosclerosis.

Research and Design Methods: ApoE-/- and RAGE-/-/ apoE-/- double knockout mice were rendered diabetic with streptozotocin and followed for 20 weeks, at which time plaque accumulation was assessed by en face analysis.

Results: Although diabetic apoE-/- mice showed increased plaque accumulation (14.9 ± 1.7%), diabetic RAGE-/-/apoE-/- mice had significantly reduced atherosclerotic plaque area (4.9 ± 0.4%) to levels not significantly different from control apoE-/- mice (4.3 ± 0.4%). These beneficial effects on the vasculature were associated with attenuation of leukocyte recruitment; decreased expression of proinflammatory mediators, including the nuclear factor-κB subunit p65, VCAM-1, and MCP-1; and reduced oxidative stress, as reflected by staining for nitrotyrosine and reduced expression of various NADPH oxidase subunits, gp91phox, p47phox, and rac-1. Both RAGE and RAGE ligands, including S100A8/A9, high mobility group box 1 (HMGB1), and the advanced glycation end product (AGE) carboxymethyllysine were increased in plaques from diabetic apoE-/- mice. Furthermore, the accumulation of AGEs and other ligands to RAGE was reduced in diabetic RAGE-/-/apoE-/- mice.

Conclusions: This study provides evidence for RAGE playing a central role in the development of accelerated atherosclerosis associated with diabetes. These findings emphasize the potential utility of strategies targeting RAGE activation in the prevention and treatment of diabetic macrovascular complications.
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 194 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 218 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Mon, 05 Jan 2015, 12:37:29 EST by Ms Kate Rowe on behalf of Learning and Research Services (UQ Library)